SCHEDULE: FMR LLC Discloses 10.8% Stake in Avalo Therapeutics
Beneficial Ownership Filing (Schedule 13G Amendment)
FMR LLC and Abigail P. Johnson have updated their Schedule 13G filing, reporting beneficial ownership of 10.8% of Avalo Therapeutics Inc.'s common stock as of July 31, 2026.
Summary
- FMR LLC, through its subsidiaries FIAM LLC, Fidelity Institutional Asset Management Trust Company, and Fidelity Management & Research Company LLC, along with Abigail P. Johnson, have filed an amended Schedule 13G.
- The filing reports beneficial ownership of 5,737,966 shares of Avalo Therapeutics Inc. common stock.
- This ownership represents 10.8% of the class of securities outstanding as of July 31, 2026.
- FMR LLC is identified as a holding company (HC), and Abigail P. Johnson is identified as an investment advisor (IA).
Sentiment
Score: 3
Explanation: StockSavvy.ai views this as a neutral filing, primarily an update on beneficial ownership rather than a performance or strategic announcement.
Future Outlook
No forward-looking statements or guidance are present in this filing.
Management Comments
- FMR LLC and Abigail P. Johnson certify that the securities were acquired and are held in the ordinary course of business and were not acquired or held for the purpose of or with the effect of changing or influencing the control of the issuer.
Industry Context
StockSavvy.ai notes that this filing is a routine Schedule 13G amendment, indicating a significant institutional investor's stake in Avalo Therapeutics. Such filings are common for asset managers and investment firms tracking their holdings.
Stakeholder Impact
- Shareholders may view the increased stake by FMR LLC as a sign of institutional confidence in Avalo Therapeutics, potentially influencing market perception.
Key Dates
| Date | Description |
|---|---|
| 01/03/2023 | Effective date of Power of Attorney for FMR LLC. |
| 01/31/2023 | Effective date of Power of Attorney for Abigail P. Johnson. |
| 07/31/2026 | Date of event requiring filing (ownership as of this date). |
| 08/06/2026 | Date of joint filing agreement and signature date. |
Keywords
beneficial ownership, Schedule 13G, FMR LLC, Avalo Therapeutics, Fidelity, investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.